Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ying, Huang, Xiao-Xiao, Chen, Guo-Bin, Wang, Ying, Zhi, Qiang, Liu, Yuan-Sheng, Wu, Xiao-Ling, Wang, Li-Fen, Yang, Bing, Xiao, Chuan-Xing, Xing, Hui-Qin, Ren, Jian-Lin, Xia, Yin, Guleng, Bayasi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216997/
https://www.ncbi.nlm.nih.gov/pubmed/27384995
http://dx.doi.org/10.18632/oncotarget.10338
Descripción
Sumario:Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel agents to overcome resistance. Dragon (also known as RGMb) is a member of the repulsive guidance molecule (RGM) family. We previously showed that Dragon expression increases with CRC progression in human patients. In the present study, we found that Dragon inhibited apoptosis and increased viability of CMT93 and HCT116 cells in the presence of oxaliplatin. Dragon induced resistance of xenograft tumor to oxaliplatinin treatment in mice. Mechanistically, Dragon inhibited oxaliplatin-induced JNK and p38 MAPK activation, and caspase-3 and PARP cleavages. Our results indicate that Dragon may be a novel target that induces drug resistance in CRC.

Ejemplares similares